Safety of endovascular treatment beyond the 6-h time window in 205 patients

Eur J Neurol. 2013 Jun;20(6):865-71. doi: 10.1111/ene.12069. Epub 2013 Jan 7.

Abstract

Background and purpose: Intra-arterial treatment (IAT) is effective when performed within 6 h of symptom onset in selected stroke patients ('T < 6H'). Its safety and efficacy is unclear when the patient has had symptoms for more than 6 h ('T > 6H') or for an unknown time (unclear-onset stroke, UOS), or woke up with a stroke (wake-up stroke, WUS). In this study we compared the safety of IAT in these four patient groups.

Methods: Eight-hundred and fifty-nine patients treated with IAT were enrolled. The main outcome parameters were clinical outcome [excellent: modified Rankin Scale (mRS) 0 or 1; or favorable: mRS 0-2] or mortality 3 months after treatment. Further outcome parameters were the rates of vessel recanalization, and cerebral and systemic hemorrhage.

Results: Six-hundred and fifty-four patients were treated before (T < 6H) and 205 after 6 h or an unknown time (128 T > 6H, 55 WUS and 22 UOS). NIHSS scores were higher in UOS patients than in T < 6H patients, vertebrobasilar occlusion was more common in T > 6H and UOS patients, and middle cerebral artery occlusions less common in T > 6H than in T < 6H patients. Other baseline characteristics were similar. There was no significant difference in clinical outcome and the rate of hemorrhage in multivariable regression analysis.

Conclusions: Clinical outcome of our four groups of patients was similar with no increase of hemorrhage rates in patients treated after awakening, after an unknown time or more than 6 h. Our preliminary data suggest that treatment of such patients may be performed safely. If confirmed in randomized trials, this would have major clinical implications.

MeSH terms

  • Aged
  • Endovascular Procedures / adverse effects
  • Endovascular Procedures / methods*
  • Female
  • Hemorrhage / chemically induced
  • Hemorrhage / diagnosis
  • Hemorrhage / epidemiology
  • Humans
  • Injections, Intra-Arterial
  • Male
  • Middle Aged
  • Prospective Studies
  • Stroke / diagnosis
  • Stroke / drug therapy
  • Stroke / prevention & control*
  • Thrombolytic Therapy / adverse effects
  • Thrombolytic Therapy / methods*
  • Time Factors
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / administration & dosage*
  • Urokinase-Type Plasminogen Activator / adverse effects

Substances

  • Urokinase-Type Plasminogen Activator